Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Go back to Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 3.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.27 | 52 Week High | $9.58 | |||
| Open | $3.27 | 52 Week Low | $2.34 | |||
| Day High | $3.27 | P/E | N/A | |||
| Day Low | $3.27 | EPS | $-0.34 | |||
| Volume | 780,024 | |||||
